A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research

Via Peters
  • Maranhão, R. C., Carvalho, P. O., Strunz, C. C. & Pileggi, F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq. Bras. Cardiol. 103, 76–84 (2014).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Schmidt, K., Noureen, A., Kronenberg, F. & Utermann, G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57, 1339–1359 (2016).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Erqou, S. et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412–423 (2009).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • McLean, J. W. et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132–137 (1987).

    ADS 
    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Lawn, R. M., Schwartz, K. & Patthy, L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc. Natl. Acad. Sci. U.S.A. 94, 11992–11997 (1997).

    ADS 
    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • van der Hoek, Y. Y., Wittekoek, M. E., Beisiegel, U., Kastelein, J. J. & Koschinsky, M. L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum. Mol. Genet. 2, 361–366 (1993).

    PubMed 
    Article 

    Google Scholar
     

  • Boerwinkle, E. et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Investig. 90, 52–60 (1992).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Romagnuolo, R., Marcovina, S. M., Boffa, M. B. & Koschinsky, M. L. Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J. Lipid Res. 55, 625–634 (2014).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Pamir, N. et al. Plasminogen promotes cholesterol efflux by the ABCA1 pathway. JCI Insight. 2(15), e92176 (2017).

    PubMed Central 
    Article 

    Google Scholar
     

  • Tavori, H. et al. Elevated Lipoprotein(a) levels lower ABCA1 cholesterol efflux capacity. J. Clin. Endocrinol. Metab. 104, 4793–4803 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Orsó, E. & Schmitz, G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin. Res. Cardiol. Suppl. 12, 31–37 (2017).

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • Tardif, J.-C., Rhéaume, E., Rhainds, D. & Dubé, M.-P. Lipoprotein (a), arterial inflammation, and PCSK9 inhibition. Eur. Heart J. 40, 2782–2784 (2019).

    PubMed 
    Article 

    Google Scholar
     

  • Albers, J. J. et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 62, 1575–1579 (2013).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Khera, A. V. et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). Circulation 129, 635–642 (2014).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nestel, P. J. et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 33, 2902–2908 (2013).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Willeit, P. et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. Lancet (London, England). 392, 1311–1320 (2018).

    CAS 
    Article 

    Google Scholar
     

  • Shapiro, M. D. et al. Relationship between low-density lipoprotein cholesterol and Lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J. Am. Heart Assoc. 8, e010932 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244–255 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Safarova, M. S. et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 14, 93–99 (2013).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl. J. Med. 382, 244–255 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Hoover-Plow, J. & Huang, M. Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabol. Clin. Exp. 62, 479–491 (2013).

    CAS 
    Article 

    Google Scholar
     

  • von Zychlinski, A., Kleffmann, T., Williams, M. J. & McCormick, S. P. Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J. Proteomics 74, 2881–2891 (2011).

    Article 
    CAS 

    Google Scholar
     

  • Seman, L. J., de Luca, C. & Jenner, J. L. Isolation and purification of serum lipoprotein (a) using lectin affinity. Methods in Mol. Biol. (Clifton, NJ). 110, 131–136 (1998).

    CAS 

    Google Scholar
     

  • Kaufman, T. M. et al. Application of PCSK9 Inhibitors In Practice. Circ. Res. 124, 32–37 (2019).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Sattler, W., Mohr, D. & Stocker, R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 233, 469–489 (1994).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Plubell, D. L. et al. High-density lipoprotein carries markers that track with recovery from stroke. Circ. Res. 127, 1274–1287 (2020).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Pamir, N. et al. Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity. J. Lipid Res. 60, 594–608 (2019).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Mueller, P. A. et al. Deletion of macrophage low-density lipoprotein receptor-Related protein 1 (LRP1) accelerates atherosclerosis regression and increases C-C chemokine receptor type 7 (CCR7) expression in plaque macrophages. Circulation 138, 1850–1863 (2018).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 101, 9774–9779 (2004).

    ADS 
    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucl. Acids Res. 47, D442-d450 (2019).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K. & Tybjærg-Hansen, A. Advances in lipid-lowering therapy through gene-silencing technologies. Nat. Rev. Cardiol. 15, 261–272 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Tsimikas, S. et al. Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet (London, England). 386, 1472–1483 (2015).

    CAS 
    Article 

    Google Scholar
     

  • Graham, M. J., Viney, N., Crooke, R. M. & Tsimikas, S. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J. Lipid Res. 57, 340–351 (2016).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Viney, N. J. et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet (London, England). 388, 2239–2253 (2016).

    CAS 
    Article 

    Google Scholar
     

  • Ruscica, M., Watts, G. F. & Sirtori, C. R. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): Making choices in an era of RNA-based therapies. Eur. J. Prev. Cardiol. 26, 998–1000 (2019).

    PubMed 
    Article 

    Google Scholar
     

  • O’Donoghue, M. L. et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139, 1483–1492 (2019).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Tavori, H. et al. PCSK9 Association With Lipoprotein(a). Circ. Res. 119, 29–35 (2016).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • von Zychlinski, A., Williams, M., McCormick, S. & Kleffmann, T. Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins. J. Proteomics 106, 181–190 (2014).

    Article 
    CAS 

    Google Scholar
     

  • Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl. J. Med. 371, 2383–2393 (2014).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl. J. Med. 364, 127–135 (2011).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Madsen, C. M., Kamstrup, P. R., Langsted, A., Varbo, A. & Nordestgaard, B. G. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler. Thromb. Vasc. Biol. 40, 255–266 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Reblin, T., Rader, D. J., Beisiegel, U., Greten, H. & Brewer, H. B. Jr. Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis 94, 223–232 (1992).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Buechler, C. et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 97, 981–986 (2001).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Buechler, C. et al. Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim. Biophys. Acta. 1642, 25–31 (2003).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Grebe, A., Hoss, F. & Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 122, 1722–1740 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260–1280 (2020).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Moeslinger, T. et al. Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett. 478, 95–99 (2000).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Berglund, L. & Ramakrishnan, R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24, 2219–2226 (2004).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Lanktree, M. B. et al. Determination of lipoprotein(a) kringle repeat number from genomic DNA: Copy number variation genotyping using qPCR. J. Lipid Res. 50, 768–772 (2009).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • https://www.nature.com/articles/s41598-022-13040-4

    Next Post

    Mother's depression symptoms from preconception to postpartum linked with children's behavioral issues

    Children whose mothers experience rising levels of depression from the period before pregnancy until the months just after giving birth are at greater risk of developing emotional, social and academic problems during their youth, UCLA psychology researchers and colleagues report. Their recently published seven-year study, which tracked mothers and their […]